Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1994-7-7
|
| pubmed:abstractText |
Recombinant human glycosylated G-CSF (rhG-CSF) may stimulate proliferation of myeloid leukemia cells and thereby increase their susceptibility to anti-cancer agents. By in vitro colony assay, the rhG-CSF-responsive NFS-60 leukemic cell clones are more effectively killed by Ara C in the presence of rhG-CSF than in the absence of rhG-CSF, while the killing of the rhG-CSF-unresponsive HL-60 cell clones is unaffected by rhG-CSF. Leukemia cell colony forming units (L-CFU) derived from most AML patients demonstrate similar results to those of the NFS-60 cell clone when treated in vitro. Encouraged by these in vitro results, we used rhG-CSF as a component of a conditioning regimen for 15 relapsed AML patients who were receiving allogeneic BMT. The patients were conditioned with total body irradiation (TBI) and high-dose Ara C. rhG-CSF was infused continuously at a dose of 5 micrograms/kg/day from 24 h before the beginning of TBI to the end of Ara C therapy. Proliferation of the leukemia cells in vivo in response to rhG-CSF was confirmed in 7 of 14 patients tested and the combined use of rhG-CSF had no additional adverse effects. After BMT, four patients died of non-leukemic causes and three patients had leukemic relapse: the other eight patients have remained disease-free for 200-1600 (median 417) days. The actuarial probabilities of relapse and disease-free survival (DFS) at 4.4 years after BMT were 43.2% and 41.7%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
239-45
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7515298-Acute Disease,
pubmed-meshheading:7515298-Adolescent,
pubmed-meshheading:7515298-Adult,
pubmed-meshheading:7515298-Bone Marrow Transplantation,
pubmed-meshheading:7515298-Combined Modality Therapy,
pubmed-meshheading:7515298-Cytarabine,
pubmed-meshheading:7515298-Dose-Response Relationship, Drug,
pubmed-meshheading:7515298-Drug Therapy, Combination,
pubmed-meshheading:7515298-Female,
pubmed-meshheading:7515298-Glycosylation,
pubmed-meshheading:7515298-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:7515298-Humans,
pubmed-meshheading:7515298-Leukemia, Myeloid,
pubmed-meshheading:7515298-Male,
pubmed-meshheading:7515298-Pilot Projects,
pubmed-meshheading:7515298-Recombinant Proteins,
pubmed-meshheading:7515298-Recurrence,
pubmed-meshheading:7515298-Tumor Cells, Cultured,
pubmed-meshheading:7515298-Whole-Body Irradiation
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia.
|
| pubmed:affiliation |
Department of Hematology-Oncology, University of Tokyo, Japan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
In Vitro
|